Advertisement
Screener

SERA PROGNOSTICS, INC. (SERA) EBITDA

SERA PROGNOSTICS, INC. (SERA) EBITDA

  • 2026-06-30: Basis Reported; EBITDA -$9.81M*; Operating income -$10.00M; Depreciation and amortization $191.00K*.
  • 2026-03-31: Basis Reported; EBITDA -$9.17M; Operating income (m); Depreciation and amortization (m).
  • 2025-12-31: Basis Reported; EBITDA -$8.71M; Operating income (m); Depreciation and amortization (m).
  • 2025-09-30: Basis Reported; EBITDA -$8.74M*; Operating income -$8.98M; Depreciation and amortization $243.00K*.

Complete source-backed ebitda history.

Available history
2020-06-30 to 2026-03-31
Data captured

Historical EBITDA

EBITDA 3 month

DateBasisEBITDAOperating incomeDepreciation and amortizationRevenueEBITDA marginCapital spendingOperating cash flowCost of products and servicesResearch and developmentSelling, general and administrationIncome tax expense / benefit
2026-06-30Reported-$9.81M*-$10.00M$191.00K*$30.00K-32710.00%*$16.00K*-$6.31M*(m)$3.49M(m)(m)
2026-03-31Reported-$9.17M(m)(m)(m)-65478.57%$8.00K-$8.77M(m)$3.03M(m)(m)
2025-12-31Reported-$8.71M(m)(m)(m)-87100.00%(m)(m)(m)(m)(m)(m)
2025-09-30Reported-$8.74M*-$8.98M$243.00K*$16.00K-54606.25%*$112.00K*-$6.48M*(m)$3.28M(m)(m)
2025-06-30Reported-$9.08M*-$9.32M$237.00K*$17.00K-53429.41%*$281.00K*-$5.47M*(m)$3.34M(m)(m)
2025-03-31Reported-$9.03M(m)(m)(m)-23773.68%$3.00K-$7.55M(m)$3.33M(m)(m)
2024-12-31Reported-$9.21M(m)(m)(m)-38383.33%(m)(m)(m)(m)(m)(m)
2024-09-30Reported-$8.66M(m)(m)(m)-29868.97%$26.00K*-$7.00M*(m)$3.50M(m)(m)
2024-06-30Reported-$9.05M(m)(m)(m)-37720.83%$7.00K*-$5.93M*(m)$4.41M(m)(m)
2024-03-31Reported-$8.88M(m)(m)(m)(m)$15.00K$4.99M(m)$3.68M(m)(m)
2023-12-31Reported-$8.64M(m)(m)(m)-21063.41%(m)(m)(m)(m)(m)(m)
2023-09-30Reported-$7.98M(m)(m)(m)-19009.52%$26.00K*-$7.59M*(m)$3.54M(m)(m)
2023-06-30Reported-$11.26M(m)(m)(m)-9154.47%$47.00K*-$7.95M*(m)$3.69M(m)(m)
2023-03-31Reported-$11.09M(m)(m)(m)-11092.00%$39.00K-$4.88M(m)$4.10M(m)(m)
2022-12-31Reported-$10.22M(m)(m)(m)-15715.38%(m)(m)(m)(m)(m)(m)
2022-09-30Reported-$10.99M(m)(m)(m)-12629.89%$372.00K*-$8.78M*(m)$4.18M(m)(m)
2022-06-30Reported-$11.55M(m)(m)(m)-14802.56%$219.00K*-$9.04M*(m)$3.26M(m)(m)
2022-03-31Reported-$12.14M(m)(m)(m)-31934.21%$7.00K-$9.56M(m)$3.32M(m)(m)
2021-12-31Reported-$12.4M(m)(m)(m)-47700.00%(m)(m)(m)(m)(m)(m)
2021-09-30Reported-$9.34M(m)(m)(m)-40617.39%$429.00K*-$9.30M*(m)$2.72M(m)(m)
2021-06-30Reported-$7.18M(m)(m)(m)-35905.00%$85.00K*-$6.24M*(m)$2.82M(m)(m)
2021-03-31Reported-$5.82M(m)(m)(m)-44800.00%$41.00K-$6.95M(m)$2.40M(m)(m)
2020-12-31Reported-$4.55M(m)(m)(m)-75866.67%(m)(m)(m)(m)(m)(m)
2020-09-30Reported-$4.44M(m)(m)(m)-88880.00%$83.00K*-$3.92M*(m)$1.89M(m)(m)
2020-06-30Reported-$4.08M(m)(m)(m)-68016.67%(m)(m)(m)$1.75M(m)(m)

EBITDA 12 month

DateBasisEBITDAOperating incomeDepreciation and amortizationRevenueEBITDA marginCapital spendingOperating cash flowCost of products and servicesResearch and developmentSelling, general and administrationIncome tax expense / benefit
2025-12-31Reported-$35.56M(m)(m)(m)-43906.17%$726.00K-$25.62M(m)$13.17M(m)$0.00
2024-12-31Reported-$35.8M(m)(m)(m)-46496.10%$56.00K-$14.19M(m)$14.73M(m)$0.00
2023-12-31Reported-$38.92M(m)(m)(m)-12719.28%$128.00K-$27.19M(m)$15.22M(m)$0.00
2022-12-31Reported-$44.9M(m)(m)(m)-16752.24%$791.00K-$34.61M(m)$14.24M(m)$0.00
2021-12-31Reported-$34.74M(m)(m)(m)-42360.98%$1.30M-$31.64M(m)$11.02M(m)$0.00
2020-12-31Reported-$17.08M(m)(m)(m)-68304.00%$149.00K-$16.87M(m)$7.78M(m)$0.00

Similar stocks

Stock NameCountryMarket CapPE Ratio
AMERICAN SHARED HOSPITAL SERVICES (AMS)United States$0.010B-5.64
Advanced Biomed Inc. (ADVB)$0.009B
Aclarion, Inc. (ACON)United States$0.008B
BioNexus Gene Lab Corp (BGLC)$0.004B
Freenome, Inc. (FRNM)United States$0.143B
EXAGEN INC. (XGN)United States$0.212B-5.95
BIODESIX INC (BDSX)United States$0.312B
Fulgent Genetics, Inc. (FLGT)United States$0.593B-6.70
Lumexa Imaging Holdings, Inc. (LMRI)United States$0.951B
CASTLE BIOSCIENCES INC (CSTL)United States$1.074B-37.45